Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of bevacizumab plus capecitabine versus capecitabine alone in elderly patients with first-line metastatic colorectal cancer
2006-003293-10Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Avastin + capecitabine with capecitabine monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Jan 2007; status: completed.
02
Drugs
bevacizumabcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-003293-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003293-10.